CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-06 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −10,283 | $16.11 | $166K | 1,291 |
| 2023-12-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −905 | 906 | ||
| 2023-12-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,506 | 12,055 | ||
| 2023-12-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,019 | 16,294 | ||
| 2023-12-06 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,853 | 123,346 | ||
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +1,400 | $1.74 | $2K | 3,009 |
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +3,200 | $2.14 | $7K | 6,209 |
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −4,600 | $16.30 | $75K | 1,609 |
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −900 | 15,108 | ||
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 10,088 | ||
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 11,894 | ||
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,200 | 37,308 | ||
| 2023-12-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,500 | 44,732 | ||
| 2023-11-27 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +2,413 | $1.74 | $4K | 3,704 |
| 2023-11-27 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +10,104 | $2.14 | $22K | 13,808 |
| 2023-11-27 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −12,517 | $16.24 | $203K | 1,291 |
| 2023-11-27 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −906 | 1,811 | ||
| 2023-11-27 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,507 | 13,561 | ||
| 2023-11-27 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,018 | 17,313 | ||
| 2023-11-27 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,086 | 130,199 |
Page 11 of 16 · 315 trades